Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Bartsch

Showing results (51-60 of 228) with videos related to

Pageof 23
Sort By:
Breast Care (Basel, Switzerland)|September 28, 2020
ASCO 2020Rupert Bartsch, Veronique Dieras, Javier Cortes, et al.
Oncology|August 22, 2012
Taxanes for ovarian cancer during pregnancy: a systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Drugs|January 17, 2025
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2- Early Breast CancerEva Valentina Klocker, Daniel Egle, Rupert Bartsch, et al.
Journal of Thoracic Disease|July 3, 2013
Challenges in managing breast cancer during pregnancyFlora Zagouri, Theodora Psaltopoulou, Constantine Dimitrakakis, et al.
Breast Care (Basel, Switzerland)|March 31, 2022
Expert Discussion: SABCS 2021Rupert Bartsch, Cornelia Kolberg-Liedtke, Guy Jerusalem, et al.
Gynecologic Oncology|September 13, 2012
mTOR inhibitors in breast cancer: a systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Gynecologic Oncology|April 17, 2012
Molecularly targeted therapies in cervical cancer. A systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Breast Care (Basel, Switzerland)|June 20, 2014
Optimal Sequencing of Anti-HER2 TherapyHans-Joachim Lück, Michael Untch, Christian Jackisch, et al.
Anti-Cancer Drugs|February 26, 2015
Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapyElisabeth S Bergen, Anna S Berghoff, Margaretha Rudas, et al.
Memo|September 28, 2020
Creating the "new normal" post-Coronavirus world-web-communication replacing face-to-face interactionWolfgang Hilbe, Andreas Pircher, Thorsten Füreder, et al.
Pageof 23

Showing results (51-60 of 228) with videos related to

Sort By:
Pageof 23
Breast Care (Basel, Switzerland)|September 28, 2020
ASCO 2020Rupert Bartsch, Veronique Dieras, Javier Cortes, et al.
Oncology|August 22, 2012
Taxanes for ovarian cancer during pregnancy: a systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Drugs|January 17, 2025
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2- Early Breast CancerEva Valentina Klocker, Daniel Egle, Rupert Bartsch, et al.
Journal of Thoracic Disease|July 3, 2013
Challenges in managing breast cancer during pregnancyFlora Zagouri, Theodora Psaltopoulou, Constantine Dimitrakakis, et al.
Breast Care (Basel, Switzerland)|March 31, 2022
Expert Discussion: SABCS 2021Rupert Bartsch, Cornelia Kolberg-Liedtke, Guy Jerusalem, et al.
Gynecologic Oncology|September 13, 2012
mTOR inhibitors in breast cancer: a systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Gynecologic Oncology|April 17, 2012
Molecularly targeted therapies in cervical cancer. A systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Breast Care (Basel, Switzerland)|June 20, 2014
Optimal Sequencing of Anti-HER2 TherapyHans-Joachim Lück, Michael Untch, Christian Jackisch, et al.
Anti-Cancer Drugs|February 26, 2015
Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapyElisabeth S Bergen, Anna S Berghoff, Margaretha Rudas, et al.
Memo|September 28, 2020
Creating the "new normal" post-Coronavirus world-web-communication replacing face-to-face interactionWolfgang Hilbe, Andreas Pircher, Thorsten Füreder, et al.
Pageof 23